Exclusive

Publication

Byline

Location

Singapore Clinical Trial: A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor

Singapore, June 4 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant V... Read More


Singapore Clinical Trial: A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease

Singapore, June 4 -- The Health Sciences Authority received information related to the study titled 'A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway ... Read More


Singapore Clinical Trial: CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Singapore, June 4 -- The Health Sciences Authority received information related to the study titled 'CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety... Read More


Singapore Clinical Trial: A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium-177 (177Lu) Rosopatamab Tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with Prostate-Specific Membrane Antigen (PSMA) Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Receptor Pathway Inhibitor (ARPI) Treatment

Singapore, June 4 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lut... Read More


Singapore Clinical Trial: CO45042: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib Plus Pembrolizumab Versus Pembrolizumab And Pemetrexed And Carboplatin or Cisplatin in Patients with Previously Untreated, KRAS G12C-Mutated, Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Singapore, June 4 -- The Health Sciences Authority received information related to the study titled 'CO45042: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib ... Read More


Singapore Clinical Trial: A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Singapore, June 4 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durv... Read More


Singapore Clinical Trial: A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX-3)

Singapore, June 4 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Soluti... Read More


Singapore Clinical Trial: RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

Singapore, June 4 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Mo... Read More


Singapore Clinical Trial: A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

Singapore, June 4 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembro... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)

Singapore, June 4 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evalu... Read More